NeuroPace (NPCE) Resumen de Acciones
NeuroPace, Inc. opera como empresa de dispositivos médicos en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en NPCE a partir de nuestros controles de riesgos.
NPCE Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de NeuroPace, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$16.92 |
| Máximo en las últimas 52 semanas | US$19.60 |
| Mínimo de 52 semanas | US$7.56 |
| Beta | 1.93 |
| Cambio en 1 mes | 0.71% |
| Variación en 3 meses | 14.95% |
| Cambio de 1 año | 33.65% |
| Variación en 3 años | 283.67% |
| Variación en 5 años | -26.94% |
| Variación desde la OPV | -32.21% |
Noticias y actualizaciones recientes
Artículo de análisis • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...
Actualización de narrativa • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.Recent updates
Artículo de análisis • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...Actualización de narrativa • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
Actualización de narrativa • Apr 15
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.
Actualización de narrativa • Apr 01
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.Actualización de narrativa • Mar 17
NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.Actualización de narrativa • Mar 03
NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.Actualización de narrativa • Feb 17
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.Actualización de narrativa • Feb 03
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.Actualización de narrativa • Jan 20
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.Artículo de análisis • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Jan 06
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.Actualización de narrativa • Dec 15
NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Artículo de análisis • Nov 19
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 25% in the...Artículo de análisis • Sep 19
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Those holding NeuroPace, Inc. ( NASDAQ:NPCE ) shares would be relieved that the share price has rebounded 25% in the...Artículo de análisis • Aug 14
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:NPCE 1 Year Share Price vs Fair Value Explore NeuroPace's Fair Values from the Community and select yours...Seeking Alpha • Jun 29
NeuroPace: Volatile, Uncertain, But Promising
Summary NeuroPace has shown strong sales growth in its core drug-resistant epilepsy market, but remains unprofitable due to ongoing R&D expenses. Recent topline momentum is impressive, with 2024 guidance raised and sales growth accelerating, yet operating losses have stopped narrowing and even increased. The NAUTILUS trial failed to meet primary endpoints for generalized epilepsy, a major setback that limits near-term market expansion potential. Despite a reasonable sales multiple and recent financing, the failed trial and persistent losses make me cautious and hesitant to increase my position. Read the full article on Seeking AlphaArtículo de análisis • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • May 13
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders would be excited to see that the share price has had a great month...
Nueva narrativa • Mar 30
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.Artículo de análisis • Mar 07
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 11% to US$11.18 in the...Artículo de análisis • Jan 24
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 26% in the...Artículo de análisis • Dec 04
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have had a really impressive month, gaining 90% after a shaky period beforehand...Artículo de análisis • Nov 14
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
A week ago, NeuroPace, Inc. ( NASDAQ:NPCE ) came out with a strong set of quarterly numbers that could potentially lead...Artículo de análisis • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Aug 03
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
It's not a stretch to say that NeuroPace, Inc.'s ( NASDAQ:NPCE ) price-to-sales (or "P/S") ratio of 2.9x right now...Artículo de análisis • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 25
NeuroPace: Picking Up The Pace
Summary NeuroPace shares have doubled since September 2023, driven by strong operating momentum. The company aims to improve the lives of epilepsy patients with its remote monitoring system, which has the potential for significant growth. Following the share price rally, I have trimmed my position but continue to hold a long position due to the company's potential and operating momentum. Read the full article on Seeking AlphaArtículo de análisis • Jan 22
Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 58% in the...Artículo de análisis • Apr 17
NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have continued their recent momentum with a 39% gain in the last month alone...Rentabilidad de los accionistas
| NPCE | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 6.8% | 1.8% | 1.2% |
| 1Y | 33.6% | -17.9% | 28.7% |
Rentabilidad vs. Industria: NPCE superó a la industria US Medical Equipment, que obtuvo un rendimiento del -17.9% el año pasado.
Rentabilidad vs. Mercado: NPCE superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.
Volatilidad de los precios
| NPCE volatility | |
|---|---|
| NPCE Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: NPCE no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NPCE (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 220 | Joel Becker | www.neuropace.com |
NeuroPace, Inc. opera como empresa de dispositivos médicos en Estados Unidos. La empresa desarrolla RNS System, un sistema de neuromodulación con respuesta cerebral que proporciona tratamiento personalizado en tiempo real en el origen del ataque para tratar la epilepsia focal resistente a los fármacos. RNS System incluye un neuroestimulador RNS, una tira cortical y cables de profundidad, un monitor remoto para el paciente y otros accesorios implantables y no implantables.
Resumen de fundamentos de NeuroPace, Inc.
| Estadísticas fundamentales de NPCE | |
|---|---|
| Capitalización bursátil | US$576.87m |
| Beneficios(TTM) | -US$21.56m |
| Ingresos (TTM) | US$99.53m |
5.8x
Ratio precio-ventas (PS)-26.8x
Ratio precio-beneficio (PE)¿Está NPCE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NPCE | |
|---|---|
| Ingresos | US$99.53m |
| Coste de los ingresos | US$21.60m |
| Beneficio bruto | US$77.93m |
| Otros gastos | US$99.49m |
| Beneficios | -US$21.56m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.63 |
| Margen bruto | 78.29% |
| Margen de beneficio neto | -21.67% |
| Ratio deuda/patrimonio | 408.3% |
¿Cómo se ha desempeñado NPCE a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/26 19:33 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
NeuroPace, Inc. está cubierta por 13 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |